top of page

Pharma & Healthcare
Covers pharmaceuticals, biotech, medical devices, diagnostics, healthcare systems, and increasingly AI applied to drug discovery and healthcare. Drug development is long, complex, and science-driven. Understanding the biology, chemistry, and clinical pipeline behind a company tells you more than its balance sheet. This category analyzes pharmaceutical and biotech opportunities through a science-first lens — from molecule to market — so you can read the opportunity before the stock price moves.


Mega-Cap Pharma Sector Analysis: Performance, Drivers & Forward Outlook
LLY, AZN, and ABBV significantly outperformed the S&P 500 over 5-10 years; JNJ, NVO, and PFE meaningfully lagged — with LLY's two GLP-1 drugs alone now over 60% of revenue. A full benchmark of all eight mega-cap pharma names, and why passive sector exposure has badly underperformed disciplined stock selection.
Apr 26


Sector Comparison Report: AI / Technology vs. Pharmaceutical Sectors
Investing in Roche, AstraZeneca, and Eli Lilly captures both the biology wave and the AI productivity wave — without paying the 35x P/E premium of pure-play AI stocks. A dimension-by-dimension comparison of AI/tech vs. pharma, ending in a specific 40-60% allocation recommendation.
Apr 26


Portfolio Strategy Report: Three Portfolio Frameworks for Global Pharma Investment
All three portfolios — Income & Stability, Balanced Growth, High Conviction — target positive long-term returns; the only real difference is how those returns arrive: dividend income or capital appreciation. Specific allocations, projected returns, and rebalancing triggers for each risk profile.
Apr 25


Investment Analysis Report: Eight Leading Pharmaceutical Companies
Four BUYs (AstraZeneca, Merck, Roche, Eli Lilly), four HOLDs, zero SELLs — a full verdict on eight leading pharma companies, scored across pipeline strength, financial health, valuation, and patent cliff exposure as of April 2026.
Apr 24


Health Care: Strategic Landscape & Implications
The highest-value health care opportunities sit at the intersection of technology, care coordination, and underserved populations — home-based care, mental health platforms, and AI-diagnostics carry the most durable structural tailwinds. A strategic map of the sector's core tensions and where each stakeholder group should focus.
Apr 22
bottom of page